The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10033 malaria professionals are enjoying the free benefits of MalariaWorld today

antigen

Open Access | Inhibitory Potential of Prodomain of Plasmodium falciparum Protease Serine Repeat Antigen 5 for Asexual Blood Stages of Parasite

January 27, 2012 - 09:06 -- Kabogo Ndegwa
Author(s): 
Asrar Alam, Virander S. Chauhan
Reference: 
PLoS ONE 7(1): e30452

MalariaWorldPlasmodium falciparum serine repeat antigen 5 (SERA5) is a target for both drug and vaccine intervention against malaria.

Medical Condition: 
Medical Treatment: 

Malaria prevalence defined by microscopy, antigen detection, DNA amplification and total nucleic acid amplification in a malaria-endemic region during the peak malaria transmission season

June 15, 2011 - 06:48 -- Kabogo Ndegwa
Author(s): 
John N. Waitumbi, Jay Gerlach, Irina Afonina, Samuel B. Anyona, Joseph N. Koros, Joram Siangla, Irina Ankoudinova, Mitra Singhal, Kate Watts, Mark E. Polhemus, Nicolaas M. Vermeulen, Walt Mahoney, Matt Steele and Gonzalo J. Domingo
Reference: 
Tropical Medicine & International Health, Volume 16, Issue 7, pages 786–793, July 2011

The prevalence of submicroscopic malaria infection was significantly higher when detecting total nucleic acid than just DNA in this outpatient population during the high transmission season.

Country: 
Medical Condition: 
Medical Treatment: 

Population genetics of malaria resistance in humans

March 29, 2011 - 07:08 -- Kabogo Ndegwa
Author(s): 
P W Hedrick
Reference: 
Heredity , (23 March 2011)

The high mortality and widespread impact of malaria have resulted in this disease being the strongest evolutionary selective force in recent human history, and genes that confer resistance to malaria provide some of the best-known case studies of strong positive selection in modern humans.

Medical Condition: 
Medical Treatment: 

Open Access | Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates

March 21, 2011 - 07:06 -- Patrick Sampao
Author(s): 
Keith Limbach , Joao Aguiar, Kalpana Gowda , Noelle Patterson , Esteban Abot , Martha Sedegah , John Sacci and Thomas Richie
Reference: 
Malaria Journal 2011, 10:65

This work identifies two promising malaria vaccine antigen candidates and suggests that a multi-antigen vaccine may be more efficacious than a single antigen vaccine.

Medical Condition: 
Medical Treatment: 

Antigen presentation in immunity to murine malaria

February 24, 2011 - 07:35 -- Kabogo Ndegwa
Author(s): 
Rachel J Lundie
Reference: 
Current Opinion in Immunology, Volume 23, Issue 1, February 2011, Pages 119-123

Understanding the initiation of cellular immune responses during blood-stage malaria infection is essential for the development of an effective vaccine that improves upon the naturally acquired immune response and induces rapid and long-lasting protection against disease.

Medical Condition: 
Medical Treatment: 

Age-dependent antibody response to Plasmodium falciparum merozoite surface protein 2 (MSP-2)

February 15, 2011 - 08:27 -- Kabogo Ndegwa
Author(s): 
A. Khosravi, M. Hommel, K. SayemiriI
Reference: 
Parasite Immunology, Volume 33, Issue 3, pages 145–157, March 2011

Merozoite surface protein 2 (MSP-2), a very immunogenic malaria antigen, is a highly polymorphic 45–53 kDa merozoite surface protein, which is regarded as a promising vaccine candidate.

Medical Condition: 
Medical Treatment: 

Open Access | Erratum: The Th1 Immune Response to Plasmodium falciparum Circumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous Insert

February 2, 2011 - 07:06 -- Kabogo Ndegwa
Author(s): 
Katarina Radosevic, Ariane Rodriguez, Angelique A. C. Lemckert, Marjolein van der Meer, Gert Gillissen, Carolien Warnar, Rie von Eyben, Maria Grazia Pau, and Jaap Goudsmit
Reference: 
Clinical and Vaccine Immunology, February 2011, p. 353, Vol. 18, No. 2

The most advanced malaria vaccine, RTS,S, is comprised of a portion of the Plasmodium falciparum circumsporozoite (CS) protein

Medical Treatment: 

Open Access | Engineering the Chloroplast Targeted Malarial Vaccine Antigens in Chlamydomonas Starch Granules

December 16, 2010 - 12:07 -- Kabogo Ndegwa
Author(s): 
David Dauvillée, Stéphane Delhaye, Sébastien Gruyer, Christian Slomianny, Samuel E. Moretz, Christophe d'Hulst, Carole A. Long, Steven G. Ball, Stanislas Tomavo
Reference: 
PLoS ONE 5(12): e15424

This novel system paves the way for the production of clinically relevant plasmodial antigens as algal starch-based particles designated herein as amylosomes, demonstrating that efficient production of edible vaccines can be genetically produced in Chlamydomonas.

Medical Condition: 
Medical Treatment: 

Production of the 42-kDa fragment of Plasmodium falciparum merozoite surface protein 1, a leading malaria vaccine antigen, in Arabidopsis thaliana seeds (pages 994–1004)

November 4, 2010 - 13:42 -- Kabogo Ndegwa
Author(s): 
On Sun Lau, Danny W.-K. Ng, Wendy W.L. Chan, Sandra P. Chang and Samuel S.M. Sun
Reference: 
Plant Biotechnology Journal, Volume 8, Issue 9, pages 994–1004, December 2010

Malaria is widely associated with poverty, and a low-cost vaccine against malaria is highly desirable for implementing comprehensive vaccination programmes in developing countries.

Medical Condition: 
Medical Treatment: 

Microbial Immunity and Vaccines: Multiple Antigen Peptide Vaccines against Plasmodium falciparum Malaria

October 22, 2010 - 10:43 -- Patrick Sampao
Author(s): 
Babita Mahajan, Jay A. Berzofsky
Reference: 
Infect. Immun., Nov 2010; 78: 4613 - 4624.

These results warrant further development and preclinical and clinical testing of the next generation of candidate MAP vaccines that are based on the conserved protective epitopes from Plasmodium antigens that are widely recognized by populations of divergent HLA types from around the world.

Medical Treatment: 

Pages

Subscribe to RSS - antigen